Loading…
Loading…
Profitability This table compares Vaxxinity and Evotec's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Vaxxinity N/A N/A N/A Evotec 20.85% 16.02% 7.81% Risk and Volatility Vaxxinity has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively,
Vaxxinity (NASDAQ: VAXX - Get Free Report) and iBio (NYSE: IBIO - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends. Analyst Ratings This is a summary of current ratings
Though it isn't unheard of for a member of Congress to have not traded any stocks after getting elected while supporting tighter regulations for politicians' equities market activity, the House and the Senate are nonetheless seemingly filled with exceptionally savvy investors.
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living.
Vaxxinity (NASDAQ: VAXX ) stock is up on Friday with heavy pre-market trading of the biotechnology company's shares. That has more than 21 million shares of VAXX stock changing hands as of this writing.
Vaxxinity (NASDAQ: VAXX ) stock is falling hard on Monday after the biotechnology company announced plans to voluntarily delist its shares from the Nasdaq Exchange. Vaxxinity will file to delist its shares on April 29, 2024.
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu.
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market (“Nasdaq”) and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Section 15(d) of the Exchange Act.
No recent filings indexed.